PRoject of Ex-Vivo vein graft ENgineering via Transfection - PREVENT IV


The goal of the trial was to evaluate treatment of vein grafts with edifoligide, an oligonucleotide decoy that binds to and inhibits E2F transcription factors and prevents neointimal hyperplasia, compared with placebo among patients undergoing coronary artery bypass graft (CABG) surgery.